EGFR and non-small cell lung carcinoma: Indeed, the TATTON study (19) was designed to test whether the combination of osimertinib and savolitinib (a potent, selective MET TKI) could overcome MET-mediated osimertinib resistance in EGFR-mutant NSCLC.